S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Georgia's largest county is still repairing damage from January cyberattack
Critical asset just had biggest fall on record (Ad)
Mistrial declared in Delaware lawsuit blaming landscaper's cancer on use of Roundup weedkiller
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Georgia's largest county is still repairing damage from January cyberattack
Critical asset just had biggest fall on record (Ad)
Mistrial declared in Delaware lawsuit blaming landscaper's cancer on use of Roundup weedkiller
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Georgia's largest county is still repairing damage from January cyberattack
Critical asset just had biggest fall on record (Ad)
Mistrial declared in Delaware lawsuit blaming landscaper's cancer on use of Roundup weedkiller
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Georgia's largest county is still repairing damage from January cyberattack
Critical asset just had biggest fall on record (Ad)
Mistrial declared in Delaware lawsuit blaming landscaper's cancer on use of Roundup weedkiller
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US

ACADIA Pharmaceuticals (ACAD) Stock Price, News & Analysis

$24.01
+0.77 (+3.31%)
(As of 03/1/2024 ET)
Today's Range
$23.35
$24.53
50-Day Range
$23.24
$31.77
52-Week Range
$17.71
$33.99
Volume
2.50 million shs
Average Volume
1.69 million shs
Market Capitalization
$3.96 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.11

ACADIA Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.87 Rating Score
Upside/​Downside
50.4% Upside
$36.11 Price Target
Short Interest
Bearish
5.72% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.01mentions of ACADIA Pharmaceuticals in the last 14 days
Based on 59 Articles This Week
Insider Trading
Selling Shares
$391,705 Sold Last Quarter
Proj. Earnings Growth
76.47%
From $0.85 to $1.50 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.99 out of 5 stars

Medical Sector

189th out of 952 stocks

Pharmaceutical Preparations Industry

79th out of 440 stocks


ACAD stock logo

About ACADIA Pharmaceuticals Stock (NASDAQ:ACAD)

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer's disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. The company was founded in 1993 and is headquartered in San Diego, California.

ACAD Stock Price History

ACAD Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Oppenheimer Keeps Their Hold Rating on ACADIA Pharmaceuticals (ACAD)
Beyond The Numbers: 13 Analysts Discuss ACADIA Pharmaceuticals Stock
See More Headlines
Receive ACAD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
3/02/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ACAD
Employees
580
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$36.11
High Stock Price Target
$95.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+50.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.87
Research Coverage
15 Analysts

Profitability

Net Income
$-215,980,000.00
Pretax Margin
-7.03%

Debt

Sales & Book Value

Annual Sales
$726.44 million
Book Value
$2.63 per share

Miscellaneous

Free Float
119,031,000
Market Cap
$3.94 billion
Optionable
Optionable
Beta
0.45
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives















ACAD Stock Analysis - Frequently Asked Questions

Should I buy or sell ACADIA Pharmaceuticals stock right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ACAD shares.
View ACAD analyst ratings
or view top-rated stocks.

What is ACADIA Pharmaceuticals' stock price target for 2024?

15 equities research analysts have issued 12-month target prices for ACADIA Pharmaceuticals' shares. Their ACAD share price targets range from $15.00 to $95.00. On average, they expect the company's share price to reach $36.11 in the next twelve months. This suggests a possible upside of 50.4% from the stock's current price.
View analysts price targets for ACAD
or view top-rated stocks among Wall Street analysts.

How have ACAD shares performed in 2024?

ACADIA Pharmaceuticals' stock was trading at $31.31 at the beginning of 2024. Since then, ACAD stock has decreased by 23.3% and is now trading at $24.01.
View the best growth stocks for 2024 here
.

Are investors shorting ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals saw a increase in short interest during the month of February. As of February 15th, there was short interest totaling 9,420,000 shares, an increase of 22.7% from the January 31st total of 7,680,000 shares. Based on an average daily volume of 1,790,000 shares, the short-interest ratio is currently 5.3 days.
View ACADIA Pharmaceuticals' Short Interest
.

When is ACADIA Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our ACAD earnings forecast
.

How were ACADIA Pharmaceuticals' earnings last quarter?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) issued its earnings results on Tuesday, February, 27th. The biopharmaceutical company reported $0.28 EPS for the quarter, missing the consensus estimate of $0.32 by $0.04. The biopharmaceutical company earned $231.04 million during the quarter, compared to analysts' expectations of $223.79 million. ACADIA Pharmaceuticals had a negative trailing twelve-month return on equity of 15.67% and a negative net margin of 8.44%. The firm's quarterly revenue was up 69.3% on a year-over-year basis. During the same period last year, the business earned ($0.26) earnings per share.

What guidance has ACADIA Pharmaceuticals issued on next quarter's earnings?

ACADIA Pharmaceuticals updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $930.0 million-$1.0 billion, compared to the consensus revenue estimate of $965.1 million.

What is Steve Davis' approval rating as ACADIA Pharmaceuticals' CEO?

8 employees have rated ACADIA Pharmaceuticals Chief Executive Officer Steve Davis on Glassdoor.com. Steve Davis has an approval rating of 88% among the company's employees.

What other stocks do shareholders of ACADIA Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA), Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD) and Exelixis (EXEL).

Who are ACADIA Pharmaceuticals' major shareholders?

ACADIA Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.16%), RTW Investments LP (6.85%), Price T Rowe Associates Inc. MD (3.15%), Palo Alto Investors LP (1.47%), First Trust Advisors LP (1.08%) and Norges Bank (0.88%). Insiders that own company stock include Austin D Kim, Austin D Kim, Brendan Teehan, Bros Advisors Lp Baker, Elena Ridloff, James Kihara, Laura Brege, Mark C Schneyer, Srdjan R Stankovic, Srdjan R Stankovic and Stephen Davis.
View institutional ownership trends
.

How do I buy shares of ACADIA Pharmaceuticals?

Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ACAD) was last updated on 3/2/2024 by MarketBeat.com Staff